PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Mar 19, 2025

Keywords

ClinConnect Summary

The PROGRESS clinical trial is exploring how a specialized approach to cancer treatment, known as precision medicine, can help patients with advanced solid tumors, including breast, lung, colorectal, and bladder cancers. The study aims to determine if having a dedicated oncology navigator and a team of experts review genetic testing results can lead to more patients receiving tailored therapies that are better suited to their specific cancer. Researchers will also look at how this approach might help more people join clinical trials and improve survival rates over a two-year period after receiving their genetic test results.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of Stage IV solid tumor cancer. They should not currently have another type of active cancer and must be eligible for a genetic test that can guide their treatment options. While the trial is not yet recruiting participants, those who join can expect support from a specialized team throughout the process, which includes reviewing their test results and guiding therapy decisions based on their unique genetic profile.

Gender

ALL

Eligibility criteria

• • In order to participate in this study a subject must meet all of the eligibility criteria outlined below.
• • Inclusion Criteria
• • Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information.
• • Subjects are willing and able to comply with study procedures based on the judgment of the investigator.
• • Age ≥ 18 years at the time of consent.
• • ECOG or Karnofsky Performance Status of 0-2.
• • Documented Stage IV solid tumor malignancy: NSCLC, CRC, Breast or Bladder Cancer
• • The treating provider deems Next Generation Sequencing (NGS) testing appropriate and plans to consider results in either first- or second-line therapy in the metastatic setting
• • A genomic tumor test has not been ordered or has been ordered but not resulted.
• Exclusion Criteria:
• • • Subjects with an active concurrent malignancy.